MindWalk Holdings (HYFT) Intangibles (2020 - 2025)
MindWalk Holdings (HYFT) posted quarterly Intangibles of $749811.5 for Q2 2025, down 97.38% year-over-year from $28.6 million in Q2 2024, and down 5.3% quarter-over-quarter from $791775.8 in Q1 2025.
MindWalk Holdings (HYFT) Intangibles (2020 - 2025) Analysis & Trends
MindWalk Holdings (HYFT) has reported Intangibles for 6 consecutive years, with $749811.5 the latest figure, recorded in Q2 2025.
- In Q2 2025, Intangibles fell 97.38% year-over-year to $749811.5; the TTM figure through Apr 2025 stood at $749811.5 (down 97.38% YoY), while the FY2025 annual figure was $765985.8, down 97.34% from the prior year.
- Intangibles fell to $749811.5 in Q2 2025 per HYFT's latest filing, from $791775.8 in the prior quarter.
- Across five years, Intangibles topped out at $32.2 million in Q2 2023 and bottomed at $749811.5 in Q2 2025.
- Historically, Intangibles has averaged $16.0 million across 5 years, with a median of $18.9 million in 2024.
- Annual changes were most pronounced in 2023 — Intangibles surged 553.48% — and 2025, when it tumbled 97.38%.
- MindWalk Holdings' Intangibles stood at $3.9 million in 2021, then jumped by 489.75% to $22.8 million in 2022, then retreated by 6.38% to $21.4 million in 2023, then declined by 21.1% to $16.8 million in 2024, then tumbled by 95.55% to $749811.5 in 2025.
- Business Quant data shows HYFT's Intangibles at $749811.5 in Q2 2025, $791775.8 in Q1 2025, and $16.8 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 749,811.51 |
| Jan 31, 2025 | 791,775.78 |
| Oct 31, 2024 | 16.85 Mn |
| Jul 31, 2024 | 17.11 Mn |
| Apr 30, 2024 | 28.63 Mn |
| Jan 31, 2024 | 20.61 Mn |
| Oct 31, 2023 | 21.35 Mn |
| Jul 31, 2023 | 22.01 Mn |
| Apr 30, 2023 | 32.23 Mn |
| Jan 31, 2023 | 23.35 Mn |
| Oct 31, 2022 | 22.81 Mn |
| Jul 31, 2022 | 23.44 Mn |
| Apr 30, 2022 | 31.28 Mn |
| Jan 31, 2022 | 3.57 Mn |
| Oct 31, 2021 | 3.87 Mn |
| Jul 31, 2021 | 4.50 Mn |
| Apr 30, 2021 | 9.45 Mn |
| Jan 31, 2021 | 5.60 Mn |
| Oct 31, 2020 | 5.87 Mn |
| Apr 30, 2020 | 8.86 Mn |